Educational reforms over a century ago established a theory to practice undergraduate medical curriculum design, in which "theory" equated with biomedical science. It is remarkable that a theory of professional knowledge that is so old has been so little challenged. We continue to assume that mastery of a rather limited canon of knowledge will lead inductively to practical competence and are surprised and disappointed when it does not. Donald Schön has written about the tension between the "high ground" of the universities and the "swampy lowlands" of practice. Gradually, the swampy lowlands have gained scholarly credibility, and a tension is becoming apparent between the competence that is needed to be an effective practitioner and the competencies that are taught in universities. Yet, there is a common desire that medicine should be a scholarly discipline. This presentation explores how theory and practice can best be integrated in the education of safe and effective practitioners. It draws on theories of training design and observational research into how medical students prepare for transition to residency. It aims to answer the question "how can medical students best prepare to prescribe effectively after starting their careers as doctors"? Disclosure of Interest: None declared.
GeNeTiCS of TreaTmeNT reSpoNSe iN depreSSioN
A. Drago * DIBINEM, Institute of Psychiatry, Bologna, Italy Summary: Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do not respond at all. Genetic factors contribute for ~50% of the AD response. During recent years, the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others. They include the cytochrome P-450 superfamily, the P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-O-methyltransferase, the monoamine oxidase A, the serotonin transporter (5-HTTLPR), the norepinephrine transporter, the dopamine transporter, variants in the 5-hydroxytryptamine receptors (5-HT1A, 5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor β -1 and α -2, the dopamine receptors (D2), the G protein β 3 subunit, the corticotropin-releasing hormone receptors (CRHR1 and CRHR2), the glucocorticoid receptors, the c-AMP response-element binding, and the brain-derived neurotrophic factor. Marginal associations were reported for angiotensin I-converting enzyme, circadian locomotor output cycles kaput protein, glutamatergic system, nitric oxide synthase, and interleukin 1-β gene. In conclusion, gene variants seem to influence human behavior, liability to disorders, and treatment response. Nonetheless, gene × environment interactions have been hypothesized to modulate several of these effects. Disclosure of Interest: None declared.
eThiCS aNd priVaCy of biobaNkS
B. Elger * University of Basel, Basel, Switzerland Summary: The advances in genetics and informatics have stimulated research involving biobanks. Research using samples and data involves privacy risks. Identifiability and its degrees have implications on determining the risk/benefit ratio of a research project. Although the need to protect confidentiality and to put in place security measures is widely recognized, terminological confusion and philosophical differences dominate the ethical and legal discussion about confidentiality of data and samples. Different mechanisms, such as coding or anonymization, influence not only privacy risks of those who supplied the biological samples but also determine whether it will be possible to communicate the results of any genetic analysis back to the research participants. Moreover, it is generally admitted that donors have the right to opt out of a biobank. This means that they may ask for destruction or unlinked anonymization of samples and data. Both can only be carried out if a link is kept between the donors and their samples and data.
In this presentation, different strategies of anonymization and coding will be described and ethical and legal arguments in favor and against them will be discussed, based on the framework of international ethical guidance and human rights implemented in Europe. (ENCePP), coordinated by the European Medicines Agency, has seen rapid growth in recent years and now accounts for > 170 partner organizations, including research centers, therapeutic networks, and data source owners. The increase in pharmacoepidemiology research via networks such as ENCePP is a clear trend to make best use of available data and expertise, through the conduct of high-quality, independent, and transparent studies focusing on safety and on benefit/risk. Through ENCePP, there is an enhanced capacity to plan and perform postauthorization studies that are essential to the monitoring of safety and efficacy of medicines throughout the product lifecycle.
Disclosure of
In addition to increasing capacity for important observational research as requested by regulatory authorities and providing a readily available pool of pharmacoepidemiology expertise, ENCePP has been instrumental in developing tools that translate guiding principles into research practice. The network's outputs include a Code of Conduct, a guide on methodologic research standards, and a Checklist for Study Protocols. These are all cited in the recently published module VIII of Good Vigilance Practice on PASS. A database of studies developed through ENCePP is currently serving as the EU PAS Register, where companies register their PASS in compliance with the provisions on transparency in the new PhV legislation. The EU PAS Register welcomes registration of studies conducted worldwide.
Current opportunities for the network include sourcing of sustainable funding for the partner organizations and existing networks involved, perceived barriers to sharing of data for studies applying for an ENCePP Study Seal, and extension of the network to research centers outside of the EU. Overcoming these challenges is important to the continued success of the network. Disclosure of Interest: None declared.
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